A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs

Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin.
The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time.
Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 [NCT06671483] or TAK-279-PsA-3002 [NCT06671496]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD).
Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.

开始日期2026-02-27

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

NCT07244263

/ Not yet recruiting临床2期

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin rubs together. They start as small bumps but may become swollen and red over time. If they fill with pus, these lumps are called abscesses; these can also burst. Over time, the area can get scars and tunnels on or under the skin. Recent studies suggest that the condition may start when hair follicles become damaged and blocked. This impacts the skin and may activate the body's germ-fighting (immune) system. This allows bacteria to grow on the skin which worsens the condition and can cause abscesses.
The main aims of this study are to learn how safe zasocitinib is, how well it works and how well adults with HS tolerate it compared with a placebo.
The participants will receive the study treatment (either zasocitinib or placebo) for up to 4 months (16 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. After the first 4 months, all participants (also those who initially received placebo) will then receive zasocitinib for up to 8 months (36 weeks).
During the study, participants will visit their study clinic 12 times.

开始日期2026-02-06

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

NCT07250802

/ Recruiting临床3期

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it.
The study will be done in 2 parts: Part A will include both children and teenagers, while part B will only include children.
At first, only teenagers who meet the study rules can participate in this study. Children may only start to participate once enough information has been collected from other studies with zasocitinib.
Participants in Part A will initially be assigned to receive either zasocitinib or placebo for the first 16 weeks of treatment, then all participants will receive zasocitinib through the end of the study. All participants in Part B will be assigned to receive treatment with zasocitinib throughout the study.
Participants will be in the study for up to 4 years and 2 months (217 weeks), including up to 35 days for the screening period, 208 weeks of treatment (Part A and Part B) and a 4-week safety follow-up period. During the study, participants will visit their study site multiple times.

开始日期2025-12-04

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

100 项与扎索替尼相关的临床结果

登录后查看更多信息

100 项与扎索替尼相关的转化医学

登录后查看更多信息

100 项与扎索替尼相关的专利（医药）

登录后查看更多信息

项与扎索替尼相关的文献（医药）

2026-01-01·PHARMACOLOGICAL REVIEWS

Leading artificial intelligence–driven drug discovery platforms: 2025 landscape and global outlook

Review

作者: Dharmasivam, Mahendiran ; Azad, Mahan Gholam ; Akinware, Adedoyin ; Kaya, Busra ; Richardson, Des R

Artificial intelligence (AI) has progressed from experimental curiosity to clinical utility, with AI-designed therapeutics now in human trials across diverse therapeutic areas. This review critically compares 5 leading AI-driven discovery platforms: generative chemistry, phenomics-first systems, integrated target-to-design pipelines, knowledge-graph repurposing, and physics-plus-machine learning design. Key developments since 2024 include positive phase IIa results for Insilico Medicine's Traf2- and Nck-interacting kinase inhibitor, ISM001-055, in idiopathic pulmonary fibrosis. Another key development was the Recursion-Exscientia merger, which integrated phenomic screening with automated precision chemistry into a full end-to-end platform. In addition, advancement of the Nimbus-originated tyrosine kinase 2 inhibitor, zasocitinib (TAK-279), into phase III clinical trials exemplifies Schrödinger's physics-enabled design strategy reaching late-stage clinical testing. Emerging platforms such as Insitro, Isomorphic Labs, Atomwise, and XtalPi illustrate the field's expanding geographic and technical footprint. SIGNIFICANCE STATEMENT: Artificial intelligence (AI) is reshaping pharmacology by shortening discovery timelines, potentially reducing attrition, and expanding the design space of therapeutic candidates. Alongside technical milestones, regulatory and ethical frameworks from the US Food and Drug Administration and European Medicines Agency are beginning to address transparency, bias, accountability, intellectual property, and data privacy. Robotics tightly integrated with AI now enables self-driving laboratories that accelerate design-make-test-learn cycles and improve reproducibility. Together, these advances chart a forward-looking roadmap in which multimodal foundation models, robotics-led platforms, and hybrid physics-AI strategies are poised to accelerate translation, derisk development, and establish trustworthy AI as a cornerstone of modern drug discovery.

2026-01-01·JOURNAL OF INVESTIGATIVE DERMATOLOGY

Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor

Article

作者: Bunick, Christopher G ; Dunbar, Faith ; McInnes, Iain B ; Kong, Kok-Fai ; Sano, Yasuyo ; Xia, Guliang ; Heap, Graham A ; Halkowycz, Petro ; Wilson, Elizabeth ; Spector, Taylor ; Durairaj, Chandra ; Mehrotra, Shailly

Zasocitinib (TAK-279) is an investigational, oral, highly selective, and potent allosteric TYK2 inhibitor. This study assessed the TYK2 inhibitory selectivity and potency of zasocitinib versus those of licensed TYK2 and Jak inhibitors. Binding affinities were determined using homogenous time-resolved fluorescence. In vitro concentration-percentage inhibition curves for IL-23-phosphorylated signal transducer and activator of transcription (pSTAT)3, type I IFN-pSTAT3, IL-12-pSTAT4, IL-2-pSTAT5, and thrombopoietin-pSTAT3 pathways were established using human whole-blood assays. Relationships between concentration and percentage inhibition were determined to estimate half-maximal inhibitory concentration. Times above half-maximal inhibitory concentration and percentage daily inhibition were modeled from simulated clinical concentrations. Zasocitinib bound the TYK2 Janus homology 2 domain with an inhibitory constant of 0.0087 nM, demonstrating more than 1 millionfold selectivity over Jak1. Zasocitinib potently inhibited TYK2 signaling, with half-maximal inhibitory concentrations of 48.2 nM (95% confidence interval = 36.8-63.1 nM), 21.6 nM (95% confidence interval = 17.3-26.9 nM), and 57.0 nM (95% confidence interval = 44.2-73.4 nM) for IL-23-pSTAT3, type I IFN-pSTAT3, and IL-12-pSTAT4 pathways, respectively; zasocitinib showed no inhibition of Jak1/2/3. Simulated clinical concentrations of 30 mg zasocitinib once daily exceeded the TYK2 half-maximal inhibitory concentration for 24 hours, maintaining >90% daily inhibition, with no Jak1/2/3 inhibition. The distinct potent and selective inhibition profile of zasocitinib defines it as a next-generation TYK2 inhibitor.

2025-12-01·JOURNAL OF INVESTIGATIVE DERMATOLOGY

Molecular, Histological, and Clinical Effects of Selective TYK2 Inhibition with Zasocitinib (TAK-279) in Patients with Moderate-to-Severe Plaque Psoriasis

Article

作者: Rambhia, Darshna ; Krueger, James G ; Blau, Jessamyn ; Kumar, Sachin ; Hong, Feng ; Tang, Jay ; Wennbo, Håkan ; Cheng, Jie ; Saha, Banishree ; Arunachalam, Vinayagam ; Kunjravia, Norma ; Choudhury, Amit ; Thakker, Paresh ; Li, Xuan ; Garcet, Sandra ; Zhang, Wenwen ; Cueto, Inna

262

项与扎索替尼相关的新闻（医药）

2026-01-16

·医药地理

2026JPM巨头亮剑！揭秘MNC王牌布局（附PPT)

2026年1月，第44届JPM医疗健康大会如期而至。全球顶尖跨国药企齐聚旧金山，在这场被誉为“医药界风向标”的盛会上，纷纷亮出未来五至十年的战略底牌。后疫情时代，行业竞争已从单一产品比拼，升级为平台技术、管线布局、全球运营与生态构建的全方位较量。本文将深度解析各大巨头在2026年的战略重心与王牌布局，揭示下一轮增长背后的逻辑与野心。默沙东（Merck & Co.）通过“科学驱动型业务发展”持续加码ADC。与第一三共合作开发的I-DXd（B7-H3 ADC）和P-DXd（HER3 ADC）已进入Ⅲ期临床，同时与科伦博泰合作开发的芦康沙妥珠单抗（TROP2 ADC）也在探索新适应症。默沙东的策略是：以KEYTRUDA为基石，通过ADC、双抗等多元技术构建肿瘤免疫联合治疗矩阵，打造超过700亿美元的商业机会。 Pharma ONE药物研发大数据平台显示，2025年芦康沙妥珠单抗（MK-2870/Sac-TMT）在全球范围内针对三阴性乳腺癌、HR阳性/HER2阴性乳腺癌、子宫内膜癌及卵巢癌等多种实体瘤，启动了多项国际多中心III期临床试验，评估其单药或与帕博利珠单抗等联合治疗的疗效与安全性。芦康沙妥珠单抗2025年关键III期临床试验一览来源：Pharma ONE药物研发大数据平台，中国医药工业信息中心点击“阅读原文”获取更多数据第一三共（Daiichi Sankyo）明确提出“成为顶级ADC公司，迈向全球肿瘤领导者”。其DXd-ADC技术平台已催生7款候选药物，ENHERTU（HER2 ADC）累计销售额突破1.5万亿日元，DATROWAY（TROP2 ADC）亦快速放量。公司计划到2030年在至少4款ADC上推出多个新适应症，覆盖患者数预计增长近6倍。第一三共的野心不仅在于输出产品，更在于确立ADC技术标准与平台领导力。诺华（Novartis）诺华聚焦四大核心治疗领域：心血管-肾-代谢、免疫、神经科学及肿瘤，依托“2+3”技术平台（化学与生物治疗为基础，xRNA、放射性配体、基因与细胞治疗为前沿），深耕美、中、德、日四大市场，通过内生研发与外部并购（如Avidity）驱动增长。其重磅管线实力雄厚：心血管领域布局abelacimab（FXI抑制剂）、pacibektug（抗IL-6单抗）及farabursen（miR-17抑制剂）三个潜在重磅药物；免疫学拥有CAR-T疗法YTB323与高亲和力IL-15抗体GIA632；神经科学重点推进remibrutinib（MS）及RNA疗法（DM1/FSHD）；肿瘤学则深化放射性配体治疗（RLT）平台，拓展Pluvicto在前列腺癌中的应用并探索新型组合。未来两年预计超15项关键临床数据提交，支撑其中长期销售中高个位数增长及2029年核心利润率重返40%以上的目标。礼来（Eli Lilly）作为全球首家“万亿俱乐部”的药企，礼来正进入“治疗肥胖及相关并发症的新时代”，战略上持续扩大产能（全球13个在建基地）并加速研发效率——其从发现到首发的周期比行业平均快3.5年，2015–2025年间共推出24个新分子实体（NMEs）。管线方面，公司重点布局抗体药物偶联物（ADC）、放射性配体疗法、siRNA、基因医学等新一代技术平台，以解决未满足的临床需求。此外，礼来积极通过外部合作与收购增强研发实力，2025年完成39笔交易，投入资本超40亿美元，并携手NVIDIA打造行业顶级超算平台，支持生物科技创新。整体战略围绕“超越分子”的创新，整合疗法、数字化与合作生态，旨在服务更广泛患者群体。罗氏（Roche）公司正着力于“下一个创新周期”，其战略核心是通过商业卓越执行、关键产品上市和管线焕新来维持增长势头。罗氏计划最大化现有产品组合（拥有17个增长强劲的重磅药物），并积极推进如giredestrant（乳腺癌）、fenebrutinib（多发性硬化症）及Gazvya（自免疾病）等关键产品的上市与拓展。公司明确目标成为全球肥胖治疗领域前三的企业，计划在2026年公布5款肥胖新药的III期启用数据。此外，罗氏高度重视合作与收购，其60%的研发管线及药品销售均涉及合作伙伴，以此加速创新。管线方面，公司布局了多达19款具备上市潜力的新分子实体，覆盖阿尔茨海默病、肿瘤、免疫等多个领域，其中多款首创/最佳（FIC/BIC）药物预计自2027年起陆续读出关键数据，旨在持续推出具有变革潜力的疗法。辉瑞（Pfizer）公司2026年的战略布局围绕四大重点展开：最大化关键交易价值（如对Seagen等的整合）、实现关键研发里程碑、投资布局2028年后增长，并规模化应用人工智能以提升整体运营效率。在肿瘤领域，多项重要资产如PADCEV（肌层浸润性膀胱癌）、ELREXFIO（多发性骨髓瘤）及PD-1xVEGF双抗（结直肠癌、肺癌等）将迎来重大进展；在免疫领域，LITFULO（利特昔替尼）将拓展至白癜风及中重度斑秃；在疫苗与预防领域，莱姆病候选疫苗及下一代肺炎球菌疫苗PCV25将推进关键研究；尤为值得注意的是其在代谢疾病的深入布局，超长效GLP-1单药及GLP-1+胰淀素复方制剂已进入中后期临床，显示出其进军肥胖治疗市场的强大决心。辉瑞正通过强化内部研发与外部收购，构建一个覆盖肿瘤、免疫、疫苗和代谢等核心治疗领域的多元化、具有持续增长潜力的产品组合。拜耳（Bayer）公司战略围绕“三支柱”展开：更新产品线、提升管线价值以及利用新运营模式。当前增长主要由前列腺癌药物Nubeqa、心肾保护药物Kerendia及眼科产品Eylea驱动，同时下一波增长将依托新上市产品Beyontra（ATTR-CM）、Lynkuet（更年期症状）及在研重磅药物Asundexian。Asundexian作为首个完成III期研究的Factor XIa抑制剂，在预防中风复发中显示出显著疗效且未增加大出血风险，具备成为变革性疗法的潜力。拜耳正通过内部研发、平台公司（如细胞与基因治疗资产）及外部合作（如与BridgeBio、Kumquat等的交易）持续补充管线，并将在2026年迎来多项关键里程碑，包括Asundexian的数据展示及Kerendia在非糖尿病慢性肾病中的III期结果。整体战略旨在重返增长轨道，并为长期发展奠定创新与效率基础。赛诺菲（Sanofi）一家 “由研发驱动、人工智能赋能的生物制药公司” ，正积极通过外部收购（如Blueprint、Dynavax）与内部研发强化管线，并持续优化产品组合与资本配置。当前增长主要由新上市产品驱动，其中血友病药物ALTUVIIIO已成为新的重磅产品。在免疫炎症、罕见病及疫苗领域，多项资产在2025年取得关键进展，包括 amiltelimab（特应性皮炎）的III期积极数据、brivekimig（化脓性汗腺炎）的II期数据，以及针对流感、狂犬病、RSV的疫苗项目。公司预计2026年将继续迎来密集的管线进展，包括lunsekimig、duvakitug（炎症性肠病）及黄热病疫苗等项目的推进，为其长期增长奠定基础。武田（Takeda）正处于增长的关键拐点，其战略核心是成为一家以创新为导向的全球生物制药企业，聚焦于胃肠道与炎症、神经科学、肿瘤三大核心治疗领域，并全面嵌入数据、数字与技术（DD&T）以提升研发与运营效率。武田计划在2026至2030年间推出多达8款具有重磅潜力的创新药物，并在未来18个月内上市三款变革性药物：overpextron（发作性睡病1型）作为首款提交NDA的食欲素激动剂，有望重塑该领域治疗格局；rusfertide（真性红细胞增多症）作为一种铁调素模拟物，能持久控制血细胞比容，满足显著未满足的临床需求；以及zasocitinib（银屑病）作为高选择性TYK2抑制剂，凭借其口服便利性和优异疗效，旨在拓展并变革高级口服疗法市场。百济神州（BeOne）致力于成为“全球领先的肿瘤公司”，以核心产品BRUKINSA（泽布替尼）为基础，通过固定疗程组合疗法ZS 拓展一线CLL市场，旨在提供兼具疗效、安全性与便利性的新一代治疗方案。在管线方面，百济神州着力推进新一代BCL-2抑制剂Sonrotoclax（已获FDA突破性疗法认定）及首创的BTK靶向蛋白降解剂（BTK CDAC）如BGB-16673，以解决耐药患者未满足的需求。同时，公司积极布局多特异性抗体、细胞疗法等新模态，计划在2026年将多款新分子实体推进至临床阶段，持续构建涵盖CLL全线治疗的领导地位，并向更广泛的肿瘤领域拓展。药明生物（WuXi Biologics）以“让天下没有难做的生物药”为愿景，打造全球领先的大规模、一体化CRDMO（合同研究、开发与生产）平台，通过持续强化在美国、新加坡及中东（如卡塔尔）等关键区域的产能与服务体系，构建覆盖生物药全生命周期的全球化、端到端服务网络。公司以双特异性/多特异性抗体、抗体偶联药物（ADC）及复杂蛋白为主要增长引擎，其中双多抗业务已成为增速最快、盈利能力最强的板块，贡献集团近20%的收入，同时依托差异化技术平台（如CD3 TCE、高剂量给药、数字化系统）和大规模生产经验，持续赋能合作伙伴推进管线。未来五年，医药行业的竞争将更加多维和立体。技术领先者将凭借平台优势持续输出新产品；疾病领域专家将在细分赛道建立护城河；生态构建者则通过诊断、治疗、服务的一体化方案赢得患者与支付方。在这场没有硝烟的战争中，唯有那些战略清晰、执行坚决、持续创新的企业，才能穿越周期，赢得未来。 2026，巨头已亮剑，战局正酣。对此您有什么看法，欢迎在评论区留言分享。关注「医药地理数据库」并回复“2026JPM”，即可获取完整PPT END 👇欢迎扫码入群 ①权威报告获取 ②医药行业情报 ③专属交流平台如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001 戳“阅读原文”试用数据库

2026-01-15

·谈医说药

2026年01月15日药品临床试验默示许可

序号受理号药品名称申请人名称适应症注册分类 1 CXSB2500225 注射用BGB-B2033 广州百济神州生物制药有限公司晚期或转移性实体瘤。 1 2 CXHL2501248 羧胺三唑软胶囊广东银珠医药科技有限公司拟用于甲氨蝶呤疗效不足或对其无法耐受的中度至重度活动性类风湿关节炎（RA）成人患者。 1 3 CXHL2501247 羧胺三唑软胶囊广东银珠医药科技有限公司拟用于甲氨蝶呤疗效不足或对其无法耐受的中度至重度活动性类风湿关节炎（RA）成人患者 1 4 CXHB2500309 TQC3721吸入粉雾剂正大天晴药业集团股份有限公司用于慢性阻塞性肺病患者的维持治疗。 1 5 CXHB2500308 TQC3721吸入粉雾剂正大天晴药业集团股份有限公司用于慢性阻塞性肺病患者的维持治疗。 1 6 CXSL2500965 CS01单抗注射液中山恒动生物制药有限公司 CS01单抗注射液I/II期临床试验方案拟定适应症为晚期实体瘤。 1 7 CYHL2500202 奥氮平萨米多芬片宜昌人福药业有限责任公司（1）成人精神分裂症；（2）成人双相Ⅰ型障碍：①单药治疗，或作为锂剂或丙戊酸盐的辅助治疗，用于躁狂或混合发作的急性治疗。②单药维持治疗。 3 8 CYHL2500201 奥氮平萨米多芬片宜昌人福药业有限责任公司（1）成人精神分裂症；（2）成人双相Ⅰ型障碍：①单药治疗，或作为锂剂或丙戊酸盐的辅助治疗，用于躁狂或混合发作的急性治疗。②单药维持治疗。 3 9 CYHL2500200 奥氮平萨米多芬片宜昌人福药业有限责任公司（1）成人精神分裂症；（2）成人双相Ⅰ型障碍：①单药治疗，或作为锂剂或丙戊酸盐的辅助治疗，用于躁狂或混合发作的急性治疗。②单药维持治疗。 3 10 CXHL2501250 QLS7305注射液齐鲁制药有限公司阵发性睡眠性血红蛋白尿（PNH） 1 11 CXSL2500913 NRG-103注射液纽伦捷生物医药科技（苏州）有限公司复发或进展的高级别脑胶质瘤 1 12 CXHL2501249 QLS7305注射液齐鲁制药有限公司原发性膜性肾病（PMN） 1 13 CXSL2500964 注射用HDM2005 杭州中美华东制药有限公司本品联合利妥昔单抗和来那度胺用于治疗复发/难治性套细胞淋巴瘤 1 14 CXSL2500963 注射用DB-1317 映恩生物科技（上海）有限公司晚期/转移性恶性实体瘤 1 15 JXHB2500155 Zasocitinib (TAK-279) 片 Takeda Development Center Americas, Inc. 成人活动性银屑病关节炎 1 16 JXHB2500154 Zasocitinib (TAK-279) 片 Takeda Development Center Americas, Inc. 成人活动性银屑病关节炎 1 17 CXHL2501237 ZL-65片成都赜灵生物医药科技有限公司冷吡啉相关周期性综合征 1 18 CXHL2501236 ZL-65片成都赜灵生物医药科技有限公司冷吡啉相关周期性综合征 1 19 CXHL2501234 ZL-65片成都赜灵生物医药科技有限公司冷吡啉相关周期性综合征 1 20 CXHL2501241 LH-2417片江苏联环药业股份有限公司本品用于前列腺肥大的男性良性前列腺增生的体征和症状的初始治疗。 2.3 21 CXHL2501240 LH-2417片江苏联环药业股份有限公司本品用于前列腺肥大的男性良性前列腺增生的体征和症状的初始治疗。 2.3 22 CXHL2501239 LH-2417片江苏联环药业股份有限公司本品用于前列腺肥大的男性良性前列腺增生的体征和症状的初始治疗。 2.3 23 CYHL2500198 艾氟洛芬贴剂四川科伦药业股份有限公司骨关节炎的镇痛、消炎。 3 24 CXSL2500959 注射用ZGGS18 苏州泽璟生物制药股份有限公司;上海泽璟医药技术有限公司注射用ZGGS18联合注射用ZG005和化疗用于晚期实体瘤（如胰腺癌、结直肠癌、非小细胞肺癌和三阴性乳腺癌等）的治疗 1 25 CXSL2500960 注射用ZG005 苏州泽璟生物制药股份有限公司;上海泽璟医药技术有限公司注射用ZG005联合注射用ZGGS18和化疗用于治疗晚期实体瘤（如胰腺癌、结直肠癌、非小细胞肺癌和三阴性乳腺癌等）的治疗。 1 26 CXHL2501228 JYP0015片广州嘉越医药科技有限公司 JYP0015联合化疗±贝伐珠单抗，或联合西妥昔单抗±化疗，或联合或不联合依沃西单抗/帕博利珠单抗/卡度尼利单抗/特瑞普利单抗±化疗±芦康沙妥珠单抗，或联合氟泽雷塞/格索雷塞/戈来雷塞±化疗，或联合呋喹替尼治疗晚期实体瘤。 1 27 CXHL2501227 JYP0015片广州嘉越医药科技有限公司 JYP0015联合化疗±贝伐珠单抗，或联合西妥昔单抗±化疗，或联合或不联合依沃西单抗/帕博利珠单抗/卡度尼利单抗/特瑞普利单抗±化疗±芦康沙妥珠单抗，或联合氟泽雷塞/格索雷塞/戈来雷塞±化疗，或联合呋喹替尼治疗晚期实体瘤。 1 28 CXHL2501226 JYP0015片广州嘉越医药科技有限公司 JYP0015联合化疗±贝伐珠单抗，或联合西妥昔单抗±化疗，或联合或不联合依沃西单抗/帕博利珠单抗/卡度尼利单抗/特瑞普利单抗±化疗±芦康沙妥珠单抗，或联合氟泽雷塞/格索雷塞/戈来雷塞±化疗，或联合呋喹替尼治疗晚期实体瘤。 1 29 CXHL2501222 IPG11406片南京艾美斐生物医药科技股份有限公司狼疮肾炎 1 30 CXHL2501221 IPG11406片南京艾美斐生物医药科技股份有限公司狼疮肾炎 1 31 CXHL2501220 IPG11406片南京艾美斐生物医药科技股份有限公司狼疮肾炎 1 32 JXSL2500211 Frexalimab注射液 Sanofi-Aventis Recherche & Développement 本品拟用于预防成人肾移植术后的移植排斥反应。 1 33 CXHL2501218 镥[177Lu]JH040182注射液晶核生物医药科技（上海）有限公司治疗成纤维细胞激活蛋白(FAP)阳性的晚期实体瘤患者。 1 34 JXHB2500153 甲磺酸贝舒地尔口服混悬剂 Sanofi-Aventis Recherche & Développement 用于治疗既往接受过至少 2 线系统性治疗后难治或复发且需要针对活动性中重度慢性移植物抗宿主病（cGVHD）接受系统性治疗的 1 至＜18 岁儿童患者。 2.2

临床1期临床2期

2026-01-15

·PMLiVE

Takeda’s zasocitinib demonstrates positive results in plaque psoriasis

Takeda’s zasocitinib has shown strong rates of skin clearance, as well as other benefits, in new study results regarding adults with moderate-to-severe plaque psoriasis (PsO). The LATITUDE phase 3 studies of zasocitinib demonstrated its superiority over placebo on both co-primary endpoints at week 16. A significant response rate was seen as early as week 4, and continued to increase through to week 24. Additionally, the studies met all ranked secondary endpoints compared to both placebo and treatment with apremilast. The safety and tolerability profiles of zasocitinib were found to be comparable with prior studies, and no new safety signals were identified. Psoriasis is a chronic immune-mediated inflammatory disease caused by skin cells multiplying too quickly. PsO is the most common form of psoriasis, and is characterised by patches of itchy, scaly and painful skin. Areas of the body where psoriatic plaques commonly form include the scalp, face, arms and elbows, legs, knees, torso, genitals, nails and in skin folds. As well as causing physical discomfort and pain, PsO can cause embarrassment, anxiety and social isolation. Around 64 million people live with psoriasis worldwide, and about 80-90% of those have PsO. Zasocitinib is an orally administered tyrosine kinase 2 (TYK2) inhibitor that maintains 24-hour inhibition of interleukin-23 and other established disease-driving immune pathways. Takeda is currently studying the safety and efficacy of zasocitinib compared with deucravacitinib in plaque psoriasis, and in phase 3 studies in psoriatic arthritis. Additional studies are also ongoing in Crohn’s disease, ulcerative colitis and vitiligo, and being initiated in hidradenitis suppurativa. Christophe Weber, president and CEO of Takeda, said: “People living with psoriasis continue to seek safe, effective and fast-acting oral therapies. These landmark results support zasocitinib’s promise to become a leading oral treatment option that can deliver clear skin for patients with PsO.”

临床结果临床3期免疫疗法

100 项与扎索替尼相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
银屑病关节炎	临床3期	美国	Takeda Pharmaceutical Co., Ltd.	2025-03-03
银屑病关节炎	临床3期	比利时	Takeda Pharmaceutical Co., Ltd.	2025-03-03
银屑病关节炎	临床3期	保加利亚	Takeda Pharmaceutical Co., Ltd.	2025-03-03
银屑病关节炎	临床3期	智利	Takeda Pharmaceutical Co., Ltd.	2025-03-03
银屑病关节炎	临床3期	哥伦比亚	Takeda Pharmaceutical Co., Ltd.	2025-03-03
银屑病关节炎	临床3期	克罗地亚	Takeda Pharmaceutical Co., Ltd.	2025-03-03
银屑病关节炎	临床3期	捷克	Takeda Pharmaceutical Co., Ltd.	2025-03-03
银屑病关节炎	临床3期	爱沙尼亚	Takeda Pharmaceutical Co., Ltd.	2025-03-03
银屑病关节炎	临床3期	德国	Takeda Pharmaceutical Co., Ltd.	2025-03-03
银屑病关节炎	临床3期	匈牙利	Takeda Pharmaceutical Co., Ltd.	2025-03-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05153148 (EULAR2025)	临床2期	银屑病关节炎	290	ZASOCITINIB 15mg	遞窪構獵鹽鹽夢獵壓襯(壓餘築鹽蓋鑰鑰鹽獵製) = 觸鏇製獵積遞壓顧製鹹壓觸鹽壓窪淵艱顧鑰齋 (糧壓鏇夢遞膚齋餘糧構 )	积极	2025-06-11
				ZASOCITINIB 30mg	遞窪構獵鹽鹽夢獵壓襯(壓餘築鹽蓋鑰鑰鹽獵製) = 餘襯鹹壓製鹽蓋網鏇蓋壓觸鹽壓窪淵艱顧鑰齋 (糧壓鏇夢遞膚齋餘糧構 )
NCT05153148 (EULAR2025)	临床2期	银屑病关节炎	290	Zasocitinib 15 mg	繭簾選範範蓋窪鬱獵構(鑰鏇積憲壓醖願壓齋糧) = Among ACR20 responders, zasocitinib-treated patients generally exhibited dose-dependent reductions from baseline in IL-6, VEGF-A, CCL8 and TWEAK at both Weeks 4 and 12. Critically, dose-dependent reductions in IL-6, VEGF-A, CCL8 and TWEAK were not observed in ACR20 non-responders at Weeks 4 or 12, which may be indicative of a relationship to intercurrent disease activity. Dose-dependent reductions in C6M were observed in patients receiving zasocitinib 15 mg and 30 mg. 餘餘獵鹽憲願繭鹹積選 (簾廠淵齋顧鏇觸鹽廠鑰 )	积极	2025-06-11
				Zasocitinib 30 mg
NCT05153148 (ACR2024)	临床2期	银屑病关节炎	290	Placebo	蓋獵衊鬱淵窪鹽醖鑰鹽(選齋憲簾積範遞鏇餘獵) = 餘願膚壓範積繭壓餘醖廠製齋糧廠築淵構鹹範 (築選鹽衊醖齋襯鑰艱衊 )	积极	2024-11-10
				Zasocitinib 5mg	鬱構淵襯網憲壓膚鹹襯(顧鑰築窪膚壓繭鹹窪窪) = 襯窪鑰淵齋鹹夢壓選構齋築廠衊願齋齋願網範 (鑰鹽艱顧襯艱膚積鹹繭 )
NCT05153148 (ACR2024)	临床2期	银屑病关节炎	290	Zasocitinib 15 mg	艱憲蓋淵選壓醖鏇衊艱(繭糧憲憲艱顧憲鑰顧選) = 選憲蓋顧築壓製繭顧鹹簾夢選簾衊範顧窪觸選 (糧觸網鏇繭膚簾構鑰積 )	积极	2024-11-10
				Zasocitinib 30 mg	艱憲蓋淵選壓醖鏇衊艱(繭糧憲憲艱顧憲鑰顧選) = 顧觸網鬱鑰膚獵觸壓齋簾夢選簾衊範顧窪觸選 (糧觸網鏇繭膚簾構鑰積 ) 更多
NCT05153148 (ACR2024)	临床2期	银屑病关节炎	290	Zasocitinib 15 mg	積網襯觸構窪醖簾鹽遞(網築鏇糧獵憲繭鏇顧顧) = 憲鑰糧齋衊鬱製鬱鑰網築觸淵遞蓋憲積遞網鬱 (願築淵膚築範積夢遞壓 )	积极	2024-11-10
				Zasocitinib 30 mg	積網襯觸構窪醖簾鹽遞(網築鏇糧獵憲繭鏇顧顧) = 選膚窪窪鏇簾鑰鹽鏇廠築觸淵遞蓋憲積遞網鬱 (願築淵膚築範積夢遞壓 )
NCT05153148 (ACR2024)	临床2期	银屑病关节炎	290	Zasocitinib 15 mg	-	积极	2024-11-10
				Zasocitinib 30 mg
NCT04999839 (Pubmed \| JAMA Dermatol) 人工标引	临床2期	斑块状银屑病	259	Zasocitinib 2 mg	壓鹹糧願積積襯遞蓋餘(範願願繭廠觸壓簾夢鏇) = 壓範鑰蓋願糧淵繭憲構獵齋膚積膚艱築築觸醖 (簾鹽壓鏇製蓋構願衊遞 )	积极	2024-10-01
				Zasocitinib 5 mg	壓鹹糧願積積襯遞蓋餘(範願願繭廠觸壓簾夢鏇) = 鏇糧顧遞淵鬱鏇壓網鑰獵齋膚積膚艱築築觸醖 (簾鹽壓鏇製蓋構願衊遞 )
NCT05153148 (CTgov)	临床2期	银屑病关节炎	305	Placebo (Placebo)	範鏇膚遞蓋鑰積齋醖顧 = 鬱憲糧壓鹽範醖製築鬱構願淵鹽膚齋範襯簾觸 (糧範簾構鑰構齋壓糧範, 憲齋獵願築窪獵淵淵蓋 ~ 壓構繭鏇簾獵膚觸鏇鏇) 更多	-	2024-05-31
				NDI-034858 (NDI-034858 Low Dose)	範鏇膚遞蓋鑰積齋醖顧 = 顧選選窪鹽獵範構糧範構願淵鹽膚齋範襯簾觸 (糧範簾構鑰構齋壓糧範, 齋繭醖淵糧蓋鏇製鏇餘 ~ 願襯膚艱鹹齋鹽製網衊) 更多
NCT05153148 (ACR2023) 人工标引	临床2期	银屑病关节炎	290	TAK-279 5TAK-279 5 mg	構衊積夢窪齋顧鹹築膚(憲窪憲夢積壓艱膚積簾) = 簾鬱構醖蓋壓餘構醖廠遞遞繭構鏇襯餘憲繭餘 (衊餘膚鹽範淵糧餘壓顧 ) 更多	积极	2023-10-24
				TAK-279 15 mg	構衊積夢窪齋顧鹹築膚(憲窪憲夢積壓艱膚積簾) = 顧簾窪餘構鹹鑰廠遞蓋遞遞繭構鏇襯餘憲繭餘 (衊餘膚鹽範淵糧餘壓顧 ) 更多
NCT04999839 (EADV2023)	临床2期	银屑病	259	TAK-279 2 mg	夢齋鏇鬱餘襯獵簾選夢(鹹衊壓網壓憲夢衊獵衊) = 鬱艱淵繭鏇夢鬱齋網衊壓網積餘廠醖願選艱製 (膚蓋廠範簾窪網膚鹽遞 ) 更多	积极	2023-10-11
				TAK-279 5 mg	夢齋鏇鬱餘襯獵簾選夢(鹹衊壓網壓憲夢衊獵衊) = 顧襯糧網齋餘憲壓襯餘壓網積餘廠醖願選艱製 (膚蓋廠範簾窪網膚鹽遞 ) 更多